Results 31 to 40 of about 32,733 (212)

Frequency of Paroxysmal Nocturnal Hemoglobinuria Clone in Turkish Myelodysplastic Syndrome Group [PDF]

open access: yes, 2018
Aim:Retrospective, cross-sectional, observational study to examine the frequency and features of paroxysmal nocturnal hemoglobinuria (PNH) clones in patients with myelodysplastic syndrome (MDS).Methods:Data were analyzed from the medical files of 41 MDS ...
Mesut Ayer   +6 more
core   +1 more source

Technical advances in flow cytometry-based diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria

open access: yesEinstein (São Paulo)
Objective: To discuss the implementation of technical advances in laboratory diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria for validation of high-sensitivity flow cytometry protocols. Methods: A retrospective study based on analysis of
Rodolfo Patussi Correia   +11 more
doaj   +1 more source

Paroxysmal nocturnal hemoglobinuria and pregnancy before the eculizumab era: the French experience

open access: yesHaematologica, 2011
Background Pregnancy in women with paroxysmal nocturnal hemoglobinuria is rare, with few reports on maternal and fetal mortality rates.Design and Methods A specific questionnaire designed to solicit data on pregnancies in women with paroxysmal nocturnal ...
Sophie de Guibert   +14 more
doaj   +1 more source

Carbamazepine-responsive paroxysmal nausea and vomiting in a patient with meningeal carcinomatosis [PDF]

open access: yes, 2006
In neurology, paroxysmal syndromes are well-known, eg, as manifestations of multiple sclerosis. We report a patient with meningeal carcinomatosis, who presented with therapyrefractory nausea and vomiting.
Borasio, Gian Domenico
core   +1 more source

Thrombolytic therapy is effective in paroxysmal nocturnal hemoglobinuria: a series of nine patients and a review of the literature

open access: yesHaematologica, 2012
Background Thrombosis is the major risk factor for death in patients with paroxysmal nocturnal hemoglobinuria. Previous case reports indicate that venous thrombosis in patients with paroxysmal nocturnal hemoglobinuria is amenable to thrombolysis.Design ...
David J. Araten   +14 more
doaj   +1 more source

Chronic Paroxysmal Hemicrania: The First Possible Bilateral Case [PDF]

open access: yes, 1986
There are three headaches syndromes that are typically characterized by strictly unilateral and always same-sided attacks: cluster headache, “cervicogenic” headache, and chronic paroxysmal hemicrania (CPH).
Pfaffenrath, Volker, Pöllmann, Walter
core   +1 more source

Effectiveness of Iptacopan Versus C5 Inhibitors in Complement Inhibitor‐Naive Patients With Paroxysmal Nocturnal Haemoglobinuria

open access: yeseJHaem
Background Paroxysmal nocturnal haemoglobinuria (PNH) is characterised by haemolytic anaemia, bone marrow failure and thrombosis. The single‐arm phase 3 APPOINT‐PNH trial (NCT04820530) investigating iptacopan monotherapy in complement inhibitor‐naive ...
Matthew Holt   +8 more
doaj   +1 more source

Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria

open access: yesHaematologica, 2014
Complement blockade by eculizumab is clinically effective in hemolytic paroxysmal nocturnal hemoglobinuria. However, the response is variable and some patients remain dependent on red blood cell transfusions.
Tommaso Rondelli   +14 more
doaj   +1 more source

COVID‐19 infection presenting as paroxysmal nocturnal hemoglobinuria

open access: yesClinical Case Reports, 2021
A diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) was elicited during acute COVID‐19 infection. COVID‐19 spike proteins trigger the alternative pathway of complement. Acute SARS‐CoV‐2 infection possibly expanded an existing PIG‐A mutation.
Adam Hines   +2 more
doaj   +1 more source

Beyond Nature's Blueprint: Macrocyclic Peptides Containing Unnatural Amino Acids in Therapeutic Development

open access: yesAngewandte Chemie International Edition, EarlyView.
Strategic incorporation of unnatural amino acids transforms macrocyclic peptides into drug‐like molecules capable of engaging challenging targets. These building blocks enhance stability, permeability, and bioavailability, accelerating the development of next‐generation peptide therapeutics.
Krishna K. Sharma   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy